問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of Urology

Division of General Surgery

Division of Hematology & Oncology

更新時間：2023-09-19

馮思中Pang, See-Tong
  • Principal Investigator
  • Clinical Trial Experience (year) 24 years

  • jacobpang@cgmh.org.tw

Recruiting Trial

55Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

馮思中

List

109Cases

2017-11-01 - 2022-06-27

Phase III

A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)

  • Condition/Disease

    Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC)

  • Test Drug

    Pembrolizumab; Epacadostat

Participate Sites
6Sites

Terminated6Sites

2022-01-01 - 2025-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2020-07-01 - 2023-06-30

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2022-01-01 - 2024-12-31

Phase II

Using 68Ga-PSMA PET/CT for the assessment of osseous tumor burden in mCRPC patients

  • Condition/Disease

    Metastatic Prostate Cancer

  • Test Drug

    Ga-68 PSMA ligand

Participate Sites
1Sites

Recruiting1Sites

2018-11-01 - 2022-05-31

Phase II

The Role of Ga68-PSMA-11 PET Imaging in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy

  • Condition/Disease

    Metastatic Prostate Cancer

  • Test Drug

    Ga-68 PSMA ligand

Participate Sites
1Sites

Recruiting1Sites

2014-01-01 - 2015-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2016-03-31 - 2020-06-30

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2020-12-01 - 2022-03-22

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2008-10-31 - 2010-06-15

Others

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2008-11-15 - 2011-05-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

1 7 8 9 10 11
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB